Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Side-effects news

Show

From To
AIDS Healthcare Foundation files two lawsuits against Gilead

Four Californians living with HIV, including one in Marin County, are suing the pharmaceutical company Gilead Sciences over its continued distribution of what they say is a toxic HIV medicine while it kept a safer version of the drug on its lab shelf to turn a higher profit.

Published
21 May 2018
From
The Bay Area Reporter
Potential safety issue affecting women living with HIV using dolutegravir at the time of conception

WHO advises that countries and ministries follow the existing 2016 WHO Consolidated ARV Guidelines, and consider the following: Pregnant women who are taking DTG should not stop their ARV therapy and should speak with their health provider for additional guidance. If other first‐line ARVs cannot be used in women of childbearing age, DTG may be considered in cases where consistent contraception can be assured.

Published
21 May 2018
From
World Health Organization
Why the Dolutegravir Pregnancy Warning is Important — and What We Should Do Now

Based on the widespread and growing use of DTG-based regimens globally, these data on the potential risks of becoming pregnant while receiving DTG have immediate and broad clinical relevance.

Published
21 May 2018
From
NEJM Journal Watch
New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir

The European Medicines Agency (EMA) is evaluating preliminary results from a study which found 4 cases of birth defects such as spina bifida (malformed spinal cord) in babies born to mothers who became pregnant while taking dolutegravir. While EMA is assessing the new evidence, dolutegravir should not be used in women seeking to become pregnant.

Published
21 May 2018
From
European Medicines Agency
Is Gilead’s Entire HIV Enterprise Built on a False Promise?

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.

Published
10 May 2018
From
Poz
Meta-analysis of dolutegravir in naive, experienced and switch studies

A meta-analysis of 7340 participants in 13 randomised trials found efficacy and safety benefits for starting dolutegravir compared with other antiretrovirals in both naive and experienced participants. In the four switch studies in participants with undetectable viral load on their current ART, however, changing to dolutegravir was associated with more adverse events and discontinuations.

Published
30 April 2018
From
HIV i-Base
TAF only superior to TDF when used with a boosting agent

The benefits of tenofovir alafenamide (TAF) over tenofovir disoproxil fumarate (TDF) may have been overstated, according to the results of a meta-analysis published in the

Published
10 April 2018
By
Michael Carter
More evidence shows Sustiva increases risk for suicidal behavior

Patients with HIV on a Sustiva-containing ART regimen had a threefold increased risk for suicidal behavior compared with ART-naive patients, according to recent data published in Clinical Infectious Diseases.

Published
26 March 2018
From
Healio
Taking multiple Rx drugs raises risks for aging adults with and without HIV

Taking five or more prescription medications increases the risk of hospitalization and death in older adults infected with HIV and comparable adults without HIV. The findings of this Yale-led study highlight the potential risks of prescribing additional drugs to patients with multiple medical conditions.

Published
01 February 2018
From
Yale News
Viral suppression protects against long-term liver damage caused by older HIV drugs

A history of treatment with some older antiretroviral drugs can have a lasting negative impact on liver health, German researchers report in PLOS One. They

Published
29 January 2018
By
Michael Carter

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.